Vistin Pharma ASA: Strong Q4 Results and Record EBITDA in 2024

Vistin Pharma ASA (VISTN), a leading producer of high-quality pharmaceuticals, has announced its financial results for the fourth quarter and preliminary results for 2024. The company's strong operational performance and strategic initiatives have contributed to a successful year, with record-breaking EBITDA and steady revenue growth.

In the fourth quarter, Vistin Pharma's revenue ended at MNOK 114, a 3% increase compared to the same quarter last year. This growth was driven by strong operational performance, which resulted in more volumes available for sale. The company's sales volume increased by 11% in the quarter, further demonstrating its ability to maintain a strong market position despite an unplanned stop on line 2 in Q1. For the full year 2024, revenue ended at MNOK 430, a 4% increase compared to the previous year, even with the unplanned stop on line 2 in Q1.

Vistin Pharma's EBITDA for the fourth quarter ended at MNOK 28, a 12% increase compared to the same quarter last year. This positive result was driven by increased sales volume and good cost control in the quarter. For the full year 2024, the company achieved an all-time high EBITDA of MNOK 104, a 21% increase compared to the previous year. This impressive growth can be attributed to the company's strategic initiatives, such as improved operational utilization of production lines, product mix optimization, and cost control measures.

The company's net profit ended at MNOK 19.4 for the fourth quarter of 2024. Vistin Pharma has a strong balance sheet, with an equity ratio of 80% and a net cash position of MNOK 13 as of year-end. Based on the preliminary 2024 results, the Board of Directors will propose for the AGM an ordinary cash dividend of total NOK 1.25 per share, to be paid in June.

Vistin Pharma's strategic initiatives have been instrumental in maintaining strong operational performance and increasing sales volume. The company has achieved an all-time high production volume of 1500MT in the third quarter, reflecting good operational utilization of both production lines. Additionally, the company has optimized its product mix, implemented good cost control measures, and expanded its production capacity to meet increased demand. These initiatives have enabled Vistin Pharma to maintain a strong market position and increase sales volume, as evidenced by the 11% increase in the fourth quarter.



In conclusion, Vistin Pharma ASA has delivered strong financial results for the fourth quarter and preliminary results for 2024, with record-breaking EBITDA and steady revenue growth. The company's strategic initiatives, such as improved operational utilization, product mix optimization, and cost control measures, have contributed to its success. With a strong balance sheet and a planned dividend, Vistin Pharma is well-positioned to continue its growth trajectory in the future.